ReviewPLoS pathogens2026
Convergent evolution of viral nucleases targeting cyclic dinucleotides.
Review in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Poxviruses, African swine fever virus (ASFV), and bacteriophages have independently evolved nucleases that degrade cyclic dinucleotides (CDNs), which are critical second messengers that mediate antiviral responses. This Pearl synthesizes recent advancements in our understanding of viral CDN-degrading nucleases and emphasizes three key themes. First, there is the conservation of CDN signaling mechanisms across different biological domains. Second, we observe the diverse structural adaptations of viral nucleases for CDN degradation. Finally, structural protein folds are conserved, allowing for functional replacements across species. Additionally, we discuss the therapeutic potential of targeting these nucleases with resistant CDN analogues and through structure-guided drug discovery. This convergence in viral immune evasion strategies provides valuable insights into the development of broad-spectrum antiviral therapies and offers new opportunities for enhancing immune responses in therapeutic contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.